PI Healthsciences announces the acquisition of Archimica S.p.A from Livia Group April 28, 2023 We are pleased to announce that today PI Healthsciences has acquired Archimica S.p.A (headquarter in Lodi, ...
IN THIS ISSUE: LIFE Goes On. Got an Urgent Project? Require Unusual Chemistry or Technology? Hydrazine. Industrial. Real The Archimica Newsletter for the Pharmaceutical Industry Spring 2023 LIFE Goes On. ...
Date: March 20th- 24th, 2023 Location: New York City, NY Archimica will attend this year´s DCAT Week from 20th to 24th of March. Since more than 75 years we focus on the ...
Announces completion of 1,5 Mio. Euro investment in continuation of its support of proven drugs using its high-compliance large-volume API capability with challenging chemistry and technology Lodi, February 3, ...
We are happy to announce that Archimica S.p.A will be exhibiting at CPhI Worldwide 2022 in Frankfurt. Our Team will attend the event from the 1st to 3rd of November ...
September 5, 2022 Archimica continues Expansion - Announces completion of its 2 Mio. Euro Investment Upgrade of its Multi-Purpose Manufacturing Capacity Archimica has started the operation of its state-of-the art ...
Archimica is happy to announce the availability of small-to large scale industrial quantities of αGPC100 (L-α-Glycerophosphoryl-choline). Since decades Archimica is a leading manufacturer of deacylated phospholipids such as L-α-Glycerophosphoryl-choline (GPC) ...
Archimica will be exhibiting at ChemOutsourcing Parsippany, New Jersey Hilton from 8 - 9 September 2022. Schedule a meeting with our team at : contact@archimica.com
Hydralazine Hydrochloride is a highly effective drug use in treatment of severe hypertension and congestive heart failure. It is proven since many years mainly as second line and/or important part ...
L-α-Glycerophosphoryl-ethanolamine, Synthesis Grade (GPE SG, see also Archimica´s API grade [Alpha-glycerylphosphorylethanolamine (GPE)] ) is a valuable advanced intermediate for the synthesis of lipids and antifungals. The high potential as intermediate ...